Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (19)

2024

  1. Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice

    Reumatologia Clinica, Vol. 20, Núm. 1, pp. 24-31

2022

  1. Development and feasibility of 4 checklists for the evaluation of comorbidity in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis: GECOAI Project

    Reumatologia Clinica, Vol. 18, Núm. 2, pp. 114-123

  2. Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review

    BMC Gastroenterology, Vol. 22, Núm. 1

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2019

  1. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

2018

  1. Recommendations for the Management of Comorbidity in Patients With Axial Spondyloarthritis in Clinical Practice

    Reumatologia Clinica, Vol. 14, Núm. 6, pp. 346-359

  2. Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis

    Reumatologia Clinica, Vol. 14, Núm. 5, pp. 254-268

  3. The EJES-3D tool for personalized prescription of exercise in axial spondyloarthritis through multimedia animations: pilot study

    Rheumatology International, Vol. 38, Núm. 7, pp. 1277-1284

2016

  1. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1875-1881

2014

  1. PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis

    Pharmacogenomics, Vol. 15, Núm. 14, pp. 1763-1769

2013

  1. Diferente expresión clínica de los pacientes con espondilitis anquilosante según el sexo en función del tiempo de evolución. Datos de REGISPONSER

    Reumatologia Clinica, Vol. 9, Núm. 4, pp. 221-225

2012

  1. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes

    Human Molecular Genetics, Vol. 21, Núm. 20, pp. 4549-4557

2011

  1. High-dose etanercept in ankylosing spondylitis: Results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)

    Rheumatology, Vol. 50, Núm. 10, pp. 1828-1837

2008

  1. Registro Nacional de Pacientes con Espondiloartritis (REGISPONSER). Análisis descriptivo de los 2.367 pacientes españoles incluidos

    Reumatologia Clinica Suplementos, Vol. 4, Núm. SUPPL. 4, pp. 48-55

2005

  1. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study

    Rheumatology, Vol. 44, Núm. 12, pp. 1555-1558

2003

  1. Infliximab in refractory spondyloarthropathies: A multicentre 38 week open study

    Annals of the Rheumatic Diseases, Vol. 62, Núm. 12, pp. 1239-1240

2001

  1. Eficacia del infliximab en espondiloartropatías refractarias. Resultados de la experiencia europea

    Revista Espanola de Reumatologia, Vol. 28, Núm. 9, pp. 400-402

  2. Valoración de la actividad, respuesta al tratamiento y criterios de refractariedad en espondiloartropatías

    Revista Espanola de Reumatologia, Vol. 28, Núm. 9, pp. 387-394